Elevance Health CEO Gail Boudreaux Buys 2,725 Shares

What Happened
Gail Boudreaux, President, CEO and Director of Elevance Health (ELV), made open-market purchases totaling 2,725 shares on July 17, 2026. The transactions consist of 2,045 shares at a weighted-average price of $368.25 (≈ $753,071) and 680 shares at a weighted-average price of $366.41 (≈ $249,159), for a combined cost of approximately $1,002,230. These were purchases (transaction code P), reported on the Form 4 filed the same day.

Key Details

• Transaction date: July 17, 2026 (filed same day; timely filing).
• Trades:
  • 2,045 shares at $368.25 (weighted average); total ≈ $753,071. Footnote F2: actual execution prices ranged $367.76–$368.69.
  • 680 shares at $366.41 (weighted average); total ≈ $249,159. Footnote F1: actual execution prices ranged $366.14–$366.48.
• Combined purchase value: ≈ $1,002,230.
• Transaction code: P = Purchase (open market).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: Each reported price is a weighted average of multiple purchases; the reporting person offers to provide full trade-by-trade details on request.
• No 10b5-1 plan, option exercises, gifts, or tax-withholding events were noted in the provided excerpt.

Context
Open-market purchases by a CEO are direct buy signals (versus routine sales) but do not on their own prove future performance. Multiple executions and small price ranges indicate the purchases were split across trades that day. Retail investors should view this as one data point and consider the company’s broader fundamentals, recent news, and other insider activity before drawing conclusions.